Ascendis Pharma A/S reports results for the quarter ended in March - Earnings Summary

Ascendis Pharma A/S

27/04/2023 22:03

* Ascendis Pharma A/S  ASND.OQ  reported a quarterly
adjusted loss
of €1.98​​ per share for the quarter ended in March. The mean
expectation of eleven analysts for the quarter was for a loss of
€2.66 per share.
    * Revenue rose 391.9% to €33.59 million from a year ago;
analysts
expected €21.53 million. 
    * Ascendis Pharma A/S's reported EPS for the quarter was a
loss of
€1.98​.
    * The mean earnings estimate of analysts had fallen by
about 0.5%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate 
    * Ascendis Pharma A/S shares had fallen by 28.7% this
quarter and
lost 37.4% so far this year.
    * The company reported a quarterly loss of €110.91 million.
    * Wall Street's median 12-month price target for Ascendis
Pharma
A/S is $142.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
April 27 at 09:02 p.m. UTC. ​All figures in euros unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -2.66          -1.98          Beat
 Dec. 31 2022      -2.56          -3.70          Missed
 Sep. 30 2022      -2.49          -3.03          Missed
 Jun. 30 2022      -2.13          -1.46          Beat